Roche Pharmaceutical Development and Sales Overview
Roche Group development pipeline
Phase I (51 NMES + 11 Als)
RG6007
RG6026
HLA-A2-WT1 x CD3
AML
glofitamab monotherapy + combos
RG6058
tiragolumab combos
heme tumors
heme & solid tumors
RG6076
CD19-4-1BBL combos
RG7827
RG7828
CHU
FAP-4-1BBL monotherapy + combos
Lunsumio (mosunetuzumab)
monotheraphy + combos
solid tumors
RG6026
glofitamab + chemo
heme tumors
tiragolumab + T
tiragolumab +T+chemo
heme tumors
glypican-3 x CD3
solid tumors
RG6058
tiragolumab + T
RG6129
RG6160
RG6171
HLA-A2-MAGE-A4 x CD3
cevostamab (FcRH5 x CD3)
giredestrant (SERD)
solid tumors
CHU
codrituzumab
HCC
tiragolumab +T
r/r multiple myeloma
CHU
CD137 switch antibody
solid tumors
solid tumors
CHU
LUNA18
solid tumors
RG6114
RG6156
inavolisib (mPI3K alpha inh)
EGFRvIII x CD3
CHU
SPYK04
solid tumors
solid tumors
RG6107
RG6139
RG6180
crovalimab
PD1 x LAG3
Phase II (21 NMES + 8 Als)
Roche
1L ctDNA high risk DLBCL
NSCLC
NSCLC neoadj-adj
cervical cancer
1L PD-L1+mSCCHN
sickle cell disease
solid tumors
autogene cevumeran + pembrolizumab
glioblastoma
SQZ
PBMC vaccine
solid tumors
RG6287
IBD
RG6180
autogene cevumeran + T
solid tumors
RG6354
RG6357
zinpentraxin alfa (PRM-151)
SPK-8011
1L melanoma
myelofibrosis
hemophilia A
RG6341
asthma
RG6185
belvarafenib (pan-RAF inh) + Cotellic + T
solid tumors
RG6358
SPK-8016
hemophilia A with inhibitors to factor VIII
RG6418
RG6189
FAP-CD40 ±T
solid tumors
selnoflast (NLRP3 inh)
inflammation
RG6149
RG6194
runimotamab (HER2 x CD3)
BC
RG6234
GPRC5D x CD3
multiple myeloma
RG6315
RG65363
RG7828
immunologic disorders
astegolimab (Anti-ST2)
COPD
RG62995
ASO factor B
IgA nephropathy
vixarelimab
immunology
RG7854/
RG6264
Phesgo OBI
RG6279
PD1-IL2v + T
RG6286
HER2+ BC
solid tumors
colorectal cancer
Lunsumio (mosunetuzumab)
RG7880
efmarodocokin alfa
SLE
aGVHD
RG6346/
TLR7 ago(3)/siRNA/PDL1 LNA
HBV
RG6084*
RG6359
SPK-3006
RG6006
Abx MCP
bacterial infections
RG6319
LepB inhibitor
complicated urinary tract infection
RG6100
semorinemab
RG6290
MAGE-A4 ImmTAC + T
solid tumors
RG6035
BS-CD20 MAb
RG6292
CD25 MAb combos
heme & solid tumors
RG6091
rugonersen (UBE3A LNA)
multiple sclerosis
Angelman syndrome
RG6102
BS-gantenerumab
RG6237
latent myostatin + Evrysdi
RG6323
IL15/IL15Ra-Fc ±T
solid tumors
RG6163
psychiatric disorders
RG6416
bepranemab
Pompe disease
Alzheimer's
Alzheimer's
SMA
Alzheimer's
RG6330
KRAS G12C
solid tumors
RG6182
RG6333
CD19 x CD28+ glofitamab
RG6344
BRAF inhibitor (3)
r/r NHL
solid tumors
RG6237
latent myostatin
RG6289
RG6392
RG6433
SHP2i combos
RG6440
TGFB (SOF 10)
RG6512
FIXa x FX
RG65261
camonsertib
oncology
solid tumors
solid tumors
hemophilia
solid tumors
RG65382
P-BCMA-ALLO1
multiple myeloma
RG7637
RG6120
RG6312
RG6351
RG65014
RG7921
CHU
VEGF-Ang2 DutaFab
neurodegenerative diseases
neuromuscular disorders
Alzheimer's
psychiatric disorders
nAMD
RG7314
balovaptan
RG7412
crenezumab
post-traumatic stress disorder
familial Alzheimer's healthy pts
RG7816
alogabat (GABA Aa5 PAM)
ASD
RG7906
ralmitaront
OpRegen
geographic atrophy
retinal disease
geographic atrophy
RG7935
RG6179
RG7774
AMY 109
endometriosis
RG7446
Morpheus platform
RG7601 Venclexta + azacitidine
RG7802
cibisatamab + T
solid tumors
r/r MDS
solid tumors
Status as of October 18, 2022
New Molecular Entity (NME)
Additional Indication (AI)
Oncology/Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other
nAMD
prasinezumab
anti-IL-6
CB2 receptor agonist
RG62995 ASO factor B
RG-No-Roche/Genentech
CHU Chugai managed
SQZ-SQZ Biotechnology managed
1Repare Therapeutics managed
2Poseida Therapeutics managed
3Kiniksa Pharmaceuticals managed
4Lineage Cell Therapeutics managed
5IONIS managed
*combination platform
T=Tecentriq
BS=Brain Shuttle
OBI-On-Body Delivery System
schizophrenia
Parkinson's
DME
DR
geographic atrophy
53View entire presentation